Publications by authors named "Mark Sborov"

Claim this Profile
R
Racial Differences in Information Needs During and After Cancer Treatment: a Nationwide, Longitudinal Survey by the University of Rochester Cancer Center National Cancer Institute Community Oncology Research Program.
Matthew Asare, Luke J Peppone, Joseph A Roscoe, Ian R Kleckner, Karen M Mustian, Mark Sborov

J Cancer Educ· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
Heather A Wakelee, Suzanne E Dahlberg, Steven M Keller, William J Tester, David R Gandara, Mark D Sborov

Lancet Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
Michael E Williams, Fangxin Hong, Randy D Gascoyne, Lynne I Wagner, John C Krauss, Mark D Sborov

Br J Haematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.
Brad S Kahl, Fangxin Hong, Michael E Williams, Randy D Gascoyne, Lynne I Wagner, Mark D Sborov

J Clin Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A computerized tool to support survivorship care.
Michele R O'Brien, Kimberly K Ness, Chara J Anderson, Mark D Sborov, Jackie D Foster

J Adv Pract Oncol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222.
Heidi Mc Kean, Philip J Stella, Shauna L Hillman, Kendrith M Rowland, Michael W Cannon, Mark D Sborov

Cancer Invest· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Stephen Jones, Christopher Stokoe, Mark Sborov, Marcus Braun, Sukumar Ethirajan

Clin Breast Cancer· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis